Research programme: antibody-drug conjugates - ADC Therapeutics/Cancer Research Technology/University of Copenhagen

Drug Profile

Research programme: antibody-drug conjugates - ADC Therapeutics/Cancer Research Technology/University of Copenhagen

Latest Information Update: 12 Jul 2016

Price : $50

At a glance

  • Originator ADC Therapeutics; Cancer Research UK; University of Copenhagen
  • Developer ADC Therapeutics; Cancer Research Technology; Cancer Research UK; University of Copenhagen
  • Class Drug conjugates; Immunoconjugates
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Research Cancer

Most Recent Events

  • 12 Jul 2016 Early research in Cancer in United Kingdom (unspecified route)
  • 12 Jul 2016 ADC Therapeutics in-licenses antibodies from Cancer Research UK and the University of Copenhagen
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top